INTERNATIONAL IMMUNOPHARMACOLOGY. 2021; 90(): 107176.
Roflupram, a novel phosphodiesterase 4 inhibitor, inhibits lipopolysaccharide-induced neuroinflammatory responses through activation of the AMPK/Sirt1 pathway
INTERNATIONAL IMMUNOPHARMACOLOGY [2021]
Dan Li, Jiangping Xu, Yunyun Qin, Ningbo Cai, Yufang Cheng, Haitao Wang